Hip studies haven't shown one common shot as the clear winner

Steroid, gel, blood-based, and salt-water shots have no clear hip winner

The stronger hip research compared steroid shots, gel shots, and blood-based shots with saline, which is sterile salt water used for a comparison. People in all the groups reported some relief. No choice clearly did better than the others.

The blood-based choice was platelet-rich plasma (PRP), made by drawing some of the patient's blood and spinning it into layers. The part with more platelets is then used for the shot. Some small studies reported better soreness and movement after PRP. Stronger comparisons gave less certain answers.

Knee findings don't settle the hip question. Biologic therapies are treatments made from material such as a patient's blood. Several knee reports found help, but others showed no clear gain. Hips move differently and sit deeper in the body.

A scan answers a separate question. It may show the same wear even when your hip feels better. Feeling less sore is not evidence that worn tissue returned.

After an exam, QC Kinetix can explain PRP and concentrated PRP, which is prepared with more platelets in a small amount, along with cost and likely follow-up.

For a visit, note changes in your sleep, walking, and dressing. Those facts show whether care made a difference you could feel. Name the daily task that matters most before discussing a shot.

Sources

1. A Bayesian network meta-analysis of 11 randomized trials (1353 patients) in hip osteoarthritis found that at 2-4 months and 6 months NO injectable - corticosteroid, hyaluronic acid or platelet-rich plasma - significantly outperformed a saline placebo injection for pain or function. Pooled change from baseline exceeded the minimal clinically important difference in every arm including placebo.

   Gazendam A, et al. — Intra-articular saline injection is as effective as corticosteroids, platelet-rich plasma and hyaluronic acid for hip osteoarthritis pain: a systematic review and network meta-analysis of randomised controlled trials.. British Journal of Sports Medicine, 2021. DOI: 10.1136/bjsports-2020-102179.

2. In a multicentre, randomized, placebo-controlled trial (n=85) of a single fluoroscopically-guided intra-articular hyaluronic acid injection for hip OA, the decrease in pain at 3 months did not differ from placebo (7.8 mm vs 9.1 mm on a 100 mm VAS; P=0.98), and responder rates were 33.3% versus 32.6%.

   Richette P, et al. — Effect of hyaluronic acid in symptomatic hip osteoarthritis: a multicenter, randomized, placebo-controlled trial.. Arthritis & Rheumatism, 2009. DOI: 10.1002/art.24301.

3. In a placebo-controlled, participant- and assessor-blinded RCT of 102 people with radiographically confirmed hip OA, 12 weeks of active physical therapy (education, manual therapy, home exercise, gait aid) did NOT beat sham ultrasound and inert gel on pain (mean difference 6.9 mm favouring sham, 95% CI -3.9 to 17.7) or function at week 13, and mild adverse effects were more common in the active group (41% vs 14%).

   Bennell KL, et al. — Effect of physical therapy on pain and function in patients with hip osteoarthritis: a randomized clinical trial.. JAMA, 2014. DOI: 10.1001/jama.2014.4591.

4. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

5. A Mayo Clinic single-blind placebo-controlled trial used each patient as their own control: 25 patients with BILATERAL knee OA received bone marrow aspirate concentrate in one knee and saline in the other. Pain fell significantly in BOTH knees at 1 week, 3 months and 6 months - and the relief, described by the authors as dramatic, did NOT differ significantly between the BMAC knee and the saline knee. No serious adverse events occurred.

   Shapiro SA, et al. — A Prospective, Single-Blind, Placebo-Controlled Trial of Bone Marrow Aspirate Concentrate for Knee Osteoarthritis.. The American journal of sports medicine, 2017. DOI: 10.1177/0363546516662455.

6. OA-11, a 56-week phase 3 double-blind placebo-controlled trial, randomized 513 knee OA patients (KL 2-3) to a single intra-articular injection of the Wnt-pathway modulator lorecivivint or vehicle placebo. Lorecivivint MISSED its primary endpoint: 12-week pain NRS change was -2.24 with drug versus -2.49 with placebo (p=0.185), no other endpoint showed a discernible treatment effect, and neither group lost meaningful medial joint space over 52 weeks. Even a purpose-built, well-funded disease-modifying candidate has not beaten a placebo injection.

   Yazici Y, et al. — A Phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis.. Clinical and experimental rheumatology, 2025. DOI: 10.55563/clinexprheumatol/hjt118.

7. FORWARD, the longest disease-modifying osteoarthritis drug trial reported to date, gave intra-articular sprifermin (a recombinant FGF-18) or placebo to knee OA patients and followed 378 of them for 5 years. Sprifermin produced a significant, sustained dose-response INCREASE in total femorotibial cartilage thickness versus placebo - and WOMAC pain improved about 50% from baseline in ALL groups, including placebo. It is the cleanest demonstration in the literature that adding measurable cartilage and relieving pain are two different results, and that one does not deliver the other.

   Eckstein F, et al. — Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.. Annals of the rheumatic diseases, 2021. DOI: 10.1136/annrheumdis-2020-219181.

8. The PRIMA trial randomized 100 patients with ankle osteoarthritis to two ultrasound-guided intra-articular PRP injections or saline placebo. AOFAS scores improved 10 points with PRP (63 to 73) and 11 points with placebo (64 to 75); the adjusted between-group difference over 26 weeks was -1 (95% CI -6 to 3, p=0.56). The authors state the results do not support using PRP for ankle osteoarthritis. The evidence for a biologic in one joint does not transfer to another.

   Paget LDA, et al. — Effect of Platelet-Rich Plasma Injections vs Placebo on Ankle Symptoms and Function in Patients With Ankle Osteoarthritis: A Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.16602.

9. A four-arm, multicentre, single-blind phase 2/3 randomized trial of 480 knee OA patients (KL II-IV) compared autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic umbilical-cord-tissue mesenchymal stromal cells against a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another, or to the corticosteroid control, and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events occurred.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

10. A randomized controlled study of 111 patients aged 18-65 with hip osteoarthritis compared three weekly ultrasound-guided injections of PRP, hyaluronic acid, or both. PRP had the lowest VAS at every follow-up and beat HA significantly at 6 months (mean VAS 21 vs 44). But the WOMAC advantage present at 2 and 6 months was NO LONGER significant at 12 months, and the combination arm did worse than PRP alone.

    Dallari D, et al. — Ultrasound-Guided Injection of Platelet-Rich Plasma and Hyaluronic Acid, Separately and in Combination, for Hip Osteoarthritis: A Randomized Controlled Study.. The American journal of sports medicine, 2016. DOI: 10.1177/0363546515620383.

11. A systematic review and meta-analysis of six Level I/II randomized trials (211 PRP and 197 hyaluronic acid patients, mean follow-up ~12 months) found NO significant difference between PRP and hyaluronic acid in WOMAC, VAS or Harris Hip Score improvement for hip osteoarthritis, including in the leukocyte-poor PRP subanalysis.

    Belk JW, et al. — Platelet-Rich Plasma Versus Hyaluronic Acid for Hip Osteoarthritis Yields Similarly Beneficial Short-Term Clinical Outcomes: A Systematic Review and Meta-analysis of Level I and II Randomized Controlled Trials.. Arthroscopy, 2022. DOI: 10.1016/j.arthro.2021.11.005.

12. A GRADE-rated systematic review and meta-analysis of 16 randomized trials (807 participants) found that MSC therapy for chronic knee OA pain PROBABLY RESULTS IN LITTLE TO NO DIFFERENCE in pain relief at 3-6 months (WMD -0.74 cm on a 10 cm VAS against a minimally important difference of 1.5 cm) or physical functioning (WMD 2.23 on the SF-36 100-point subscale against a 10-point MID), both moderate certainty; at 12 months pain was again probably little-to-no-different (WMD -0.73 cm). The measured effect is real but sits BELOW the threshold at which a patient would notice it.

    Sadeghirad B, et al. — Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials.. Osteoarthritis and cartilage, 2024. DOI: 10.1016/j.joca.2024.04.021.

13. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit.

    Awad G, et al. — Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.. Clinical rheumatology, 2026. DOI: 10.1007/s10067-026-08042-w.

14. The strongest recent POSITIVE signal: a meta-analysis of 10 RCTs (818 patients, KL I-III) found intra-articular MSC injection beat hyaluronic acid at 12 months on WOMAC total (MD -10.22), VAS (MD -1.31) and on the MRI Whole-Organ Magnetic Resonance Imaging Score (MD -26.01), all reaching the minimal clinically important difference, with no significant difference in adverse events. Recorded here at full weight: this result and the negative RESTORE and Mautner trials are both in the literature, and an honest page reports both.

    Jin WS, et al. — Mesenchymal Stem Cells Injection Is More Effective Than Hyaluronic Acid Injection in the Treatment of Knee Osteoarthritis With Similar Safety: A Systematic Review and Meta-analysis.. Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association, 2025. DOI: 10.1016/j.arthro.2024.07.027.

15. A Level-1 systematic review of 8 randomized trials (937 patients) of bone marrow aspirate concentrate for knee OA found BMAC improved clinical scores versus baseline from one month, and beat hyaluronic acid on pain at 6 and 12 months with statistical significance - but those differences DID NOT EXCEED the minimal clinically important difference, and against other injections no significant difference appeared at all. Statistically detectable is not the same as noticeable.

    Han JH, et al. — Bone Marrow Aspirate Concentrate Injections for the Treatment of Knee Osteoarthritis: A Systematic Review of Randomized Controlled Trials.. Orthopaedic journal of sports medicine, 2024. DOI: 10.1177/23259671241296555.

16. A meta-analysis of 9 Level-1 trials (671 patients) of adipose stromal vascular fraction and adipose-derived MSC injections for knee OA found SVF superior to saline or hyaluronic acid on pain and function at 3, 6 and 12 months - but INFERIOR to corticosteroid at 3 months, no different at 6, and only comparable or slightly superior at 12. Adipose-derived MSCs beat saline and conservative care but showed no significant difference versus HA. No serious adverse events were attributed to the injections themselves, though complications associated with the LIPOSUCTION step were observed.

    Han JH, et al. — Intra-articular Stromal Vascular Fraction and Mesenchymal Stem Cell Injections Show Variable Efficacy and Higher Potential Complications Compared to Corticosteroid and Hyaluronic Acid in Treatment of Knee Osteoarthritis: A Meta-analysis of Randomized Controlled Trials.. Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association, 2025. DOI: 10.1016/j.arthro.2025.01.050.

17. The 2026 Cochrane update of exercise for hip osteoarthritis (18 trials, 1368 participants) found that against attention control or placebo, exercise may have little to no effect on pain (MD -6.31 points on 0-100, 95% CI -12.98 to 0.35, low certainty) and may improve physical function only slightly; against no treatment or usual care it probably reduces pain slightly (MD -7.19, 95% CI -10.70 to -3.68, moderate certainty) but the review states these improvements are unlikely to be clinically meaningful. This is a weaker result than the equivalent knee evidence and it must not be overstated.

    Hall M, et al. — Exercise for osteoarthritis of the hip.. Cochrane Database of Systematic Reviews, 2026. DOI: 10.1002/14651858.CD007912.pub3.

18. The AAOS evidence-based clinical practice guideline on Management of Osteoarthritis of the Hip states verbatim: STRONG evidence supports intra-articular corticosteroids to improve function and reduce pain in the SHORT TERM; STRONG evidence does NOT support intra-articular hyaluronic acid, because it does not perform better than placebo for function, stiffness and pain; STRONG evidence supports physical therapy for mild to moderate symptoms; STRONG evidence supports NSAIDs for short-term pain and function; and MODERATE evidence does not support glucosamine sulfate.

    American Academy of Orthopaedic Surgeons — Management of Osteoarthritis of the Hip: Evidence-Based Clinical Practice Guideline.. AAOS, 2017.